drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Adoptive cellular gene therapy using T cells engineered with a chimeric antigen receptor (e.g., anti-CD19) to target and eliminate malignant B cells in DLBCL.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor (e.g., anti-CD19) that binds antigen on malignant B cells independent of MHC, activating the T cells to proliferate, release cytokines, and kill target cells via perforin/granzyme-mediated cytotoxicity, resulting in elimination of the tumor.
drug_name
CAR-T cell therapy
nct_id_drug_ref
NCT06439173